Tilray Brands's EBIT per Share for the
three
months ended in Feb. 2026 was C$-0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 was C$-20.10.
During the past 3 years, the average EBIT per Share Growth Rate was 37.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 14.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Tilray Brands's EBIT per Share or its related term are showing as below:
TSX:TLRY'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -164.1 Med: -8.2 Max: 37
Current: 37
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Tilray Brands was 37.00% per year. The lowest was -164.10% per year. And the median was -8.20% per year.
TSX:TLRY's 3-Year EBIT Growth Rate is ranked better than 82% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs TSX:TLRY: 37.00
Tilray Brands's EBIT for the
three
months ended in Feb. 2026 was C$-25 Mil.
Tilray Brands (TSX:TLRY) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Tilray Brands EBIT per Share Related Terms
Tilray Brands EBIT per Share Historical Data
* Premium members only.
The historical data trend for Tilray Brands's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-20.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tilray Brands (TSX:TLRY) has a EBIT per Share of C$-20.10 as of Feb. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tilray Brands and its competitors. According to the industry distribution chart, Tilray Brands ranks #146 out of 811 companies in the Drug Manufacturers industry, placing it in the top 18%.
Is Tilray Brands' EBIT per Share too high?
Tilray Brands' current EBIT per Share is C$-20.10. Based on the distribution chart, Tilray Brands ranks #146 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tilray Brands has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tilray Brands' EBIT per Share compare to AQST and EOLS?
According to the Drug Manufacturers industry distribution chart, Tilray Brands ranks #146 out of 811 companies for EBIT per Share. This places Tilray Brands in the top 18% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tilray Brands and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tilray Brands's current EBIT per Share is C$-20.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tilray Brands stock overvalued right now?
Based on GuruFocus' analysis, Tilray Brands (TSX:TLRY) is currently considered Possible Value Trap. The stock's GF Value™ is C$17.54, compared to a current price of C$6.56 — trading 62.6% below its estimated fair value. The current EBIT per Share is C$-20.10. Tilray Brands' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Tilray Brands (TSX:TLRY), the current EBIT per Share is C$-20.10 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tilray Brands (TSX:TLRY) Overvalued in 2026?
Based on GuruFocus' analysis, Tilray Brands stock appears to be undervalued.
The current stock price of C$6.56 is trading 62.6% below its estimated GF Value™ of C$17.54.
GuruFocus considers Tilray Brands to be Possible Value Trap.
Key valuation signals for TSX:TLRY:
EBIT per Share: C$-20.10
GF Value™: C$17.54 vs. price of C$6.56 (62.6% below fair value)
No single metric tells the full story. See the TSX:TLRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
61GF Score
Get the complete analysis for TSX:TLRY
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:TLRY has been successfully added to your 
